Head to Head Analysis: BioNano Genomics (NASDAQ:BNGO) and Fluidigm (FLDM)

BioNano Genomics (NASDAQ:BNGO) and Fluidigm (NASDAQ:FLDM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, institutional ownership, risk and profitability.

Institutional & Insider Ownership

80.3% of BioNano Genomics shares are held by institutional investors. Comparatively, 98.3% of Fluidigm shares are held by institutional investors. 2.2% of Fluidigm shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.


This table compares BioNano Genomics and Fluidigm’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioNano Genomics N/A N/A N/A
Fluidigm -50.46% -86.00% -11.01%

Analyst Ratings

This is a breakdown of current ratings for BioNano Genomics and Fluidigm, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioNano Genomics 0 0 2 0 3.00
Fluidigm 0 0 1 0 3.00

BioNano Genomics currently has a consensus price target of $12.00, suggesting a potential upside of 76.47%. Fluidigm has a consensus price target of $6.10, suggesting a potential downside of 24.78%. Given BioNano Genomics’ higher possible upside, equities research analysts clearly believe BioNano Genomics is more favorable than Fluidigm.

Valuation & Earnings

This table compares BioNano Genomics and Fluidigm’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioNano Genomics $9.50 million 7.18 -$23.36 million N/A N/A
Fluidigm $101.94 million 3.13 -$60.53 million ($1.19) -6.82

BioNano Genomics has higher earnings, but lower revenue than Fluidigm.


BioNano Genomics beats Fluidigm on 7 of the 10 factors compared between the two stocks.

BioNano Genomics Company Profile

BioNano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. Its Saphyr system comprises an instrument, chip consumables, reagents, and a suite of data analysis tools. BioNano Genomics, Inc. also provides Bionano prep kits and labeling kits that provide the critical reagents and protocols needed to extract and label high molecular weight, or HMW, DNA for use with the Saphyr system; and data solutions that includes a suite of hardware and software for experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. The company was formerly known as BioNanomatrix, Inc. and changed its name to BioNano Genomics, Inc. in October 2011. The company was founded in 2003 and is headquartered in San Diego, California.

Fluidigm Company Profile

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell genomics that comprise C1 system, Polaris system, C1 IFCs, and Polaris IFC. It sells instruments and consumables, including IFCs, assays, and reagents to academic institutions, clinical research laboratories, and contract research organizations, as well as biopharmaceutical, biotechnology, and agricultural biotechnology companies. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.

Receive News & Ratings for BioNano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNano Genomics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Leave a Reply